All In Biotech

NDA 021524 · Prof Dspls

Prevantics Swabstick

Chlorhexidine Gluconate, Isopropyl Alcohol · Topical

Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 3, 2005

Approved uses

2

Original approval plus efficacy supplements

Registered trials

551

112 Phase 3, 30 recruiting

FAERS reports

23

20 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 10, 2025.

Use for the preparation of the patient's skin prior to surgery or injection

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 14, 2018 Supplement 12 · Efficacy Letter
  • Jun 3, 2005 Original approval · Type 3 - New Dosage Form LetterLabelReview
3 products under this application
  • PREVANTICS SWABSTICK · CHLORHEXIDINE GLUCONATE 3.15%; ISOPROPYL ALCOHOL 70% (1.6ML) · SWAB, TOPICAL · Over-the-counter
  • PREVANTICS MAXI SWABSTICK · CHLORHEXIDINE GLUCONATE 3.15%; ISOPROPYL ALCOHOL 70% (5.1ML) · SWAB, TOPICAL · Over-the-counter
  • PREVANTICS SWAB · CHLORHEXIDINE GLUCONATE 3.15%; ISOPROPYL ALCOHOL 70% (1ML) · SWAB, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorhexidine Gluconate" as an intervention, any sponsor and status, largest first.

All 551 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hand deformity16
  • helicobacter infection16
  • rheumatoid arthritis16
  • swelling16
  • systemic lupus erythematosus16
  • glossodynia15
  • infusion related reaction15
  • joint swelling15
  • synovitis15
  • wound15
  • rash14
  • duodenal ulcer perforation13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20162
20171
20201
20223
20234
20248
20251
20262

Recalls

3 FDA enforcement reports for this application.

  • Feb 4, 2022 · Class II · Terminated

    cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

  • Feb 4, 2022 · Class II · Terminated

    cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

  • Feb 4, 2022 · Class II · Terminated

    cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 571 on PubMed

Sponsor: Prof Dspls · Also marketed as Prevantics Maxi Swabstick, Prevantics Swab

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.